Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Single Ascending Dose Study of TS-142 in Healthy Volunteers
NCT04169893Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Oct 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vornorexant in Insomnia (7 arms), sponsored by Taisho Pharmaceutical. Primary endpoints: Incidence of Treatment-emergent Adverse Events and Serious Adverse Events and Area under the concentration-time curve AUC (tau) at 48 hours. Started Oct 2015; status: completed.
02
Drugs
vornorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT04169893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04169893.